Skip to content
Entelexo Biotherapeutics logo

Entelexo Biotherapeutics

Entelexo Biotherapeutics is a YC Winter 2021 (W21) company. Based in Irvine, CA, USA. Team of 3.

  • Biotech

About Entelexo Biotherapeutics

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

Entelexo Biotherapeutics develops engineered exosome-based therapeutics for autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis. Its platform engineers exosomes to deliver signals to multiple specific cell types simultaneously, targeting several disease pathways at once. This contrasts with existing single-cytokine-blocking drugs, which treat all patients identically and leave the underlying disease complexity unaddressed.

From the Y Combinator listing

How Entelexo Biotherapeutics describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

Creating a New Class of Drugs to Address Incurable Autoimmune Diseases

Entelexo is creating modern treatments for immune-mediated diseases, such as psoriasis, using novel engineered exosome technology.

Facts

Industry
Healthcare / Healthcare -> Therapeutics
Location
Irvine, CA, USA
Team size
3
Status
Active
Stage
Early

Founders (3)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works